Michael Wang, MD
@michaelwangmd
Followers
7K
Following
6K
Media
660
Statuses
3K
Puddin Clarke Endowed Professor, #Lymphoma/#Myeloma @MDAndersonnews; #mantlecelllymphoma, B-Cell Lymphoma Moonshot, MD Anderson https://t.co/0WoQhmrFHO views=own
Houston, Texas
Joined January 2015
This article was epublished in an high impact journal “Blood” last week. It is a brand new approach to drug resistance! We thank all people who support our research!.
In MCL, pirtobrutinib creates drug-tolerant persister cells via a nongenetic metabolic switch; targeting these cells could overcome drug resistance.
5
5
40
In MCL, pirtobrutinib creates drug-tolerant persister cells via a nongenetic metabolic switch; targeting these cells could overcome drug resistance.
1
7
47
RT @MikkaelSekeres: Our deep dive (with @NamrataChandhok) on Measurable Residual Disease in hematologic malignancies: a biomarker in search….
0
18
0
RT @bdermanmd: In-vivo CAR Ts for myeloma are going to come fast and furious. These products are engineering marvels. ESO-T01 (EsoBiotec)….
0
43
0
RT @lymphomahub: CONGRESS | #18ICML | PRESENTATION.Michael Wang @michaelwangmd @MDAndersonNews discusses results from the SYMPATICO study o….
0
20
0
RT @lymphomahub: CONGRESS | #18ICML2025 | PRESENTATION.L. Elizabeth Budde (@elizabeth_budde), @CityofHope presents interim phase II Morning….
0
5
0
RT @lymphomahub: CONGRESS | #18ICML | David A. Russler-Germain @dgermain21 @SitemanCenter discusses three identified Large B-cell Lymphoma….
0
12
0
RT @AuclairDan: Dr. Daisy Diaz presenting at #EHA2025 multiomics analysis of R/R CLL resistant to venetoclax and BTKis identifying multiple….
0
8
0
RT @doctorpemm: #EHA25 #EHA2025 Thank you 🙏 #Milano 🇮🇹 for hosting us @EHA_Hematology | See you at #EHA2026 #EHA26 ! @harrisoncn1 @mpdrc @N….
0
8
0
RT @DrRaulCordoba: What a great honor to present the updated data of BGB-11417-101 trial exploring #sonrotoclax + #zanubrutinib in R/R MCL….
0
6
0
RT @lymphomahub: CONGRESS | #EHA2025 | PRESENTATION.@DrRaulCordoba @Hospital_FJD discusses updated safety and efficacy results for patients….
0
8
0
RT @AuclairDan: Sonrotoclax + zanubrutinib in R/R MCL at #EHA2025 . Encouraging safety and antitumor activity at RP2D with ORR of 78% and a….
0
15
0
RT @Pavlovsky_Mig: EHA 2025 - ECHO trial: nice to be part of an international effort thanks to our patients and wonderful team at FUNDALEU….
0
10
0
RT @AuclairDan: Dr. Anna Maria Frustaci presenting BTK degrader BGB-16674 CaDAnce-101 Ph1 R/R WM study at #EHA2025 Good safety profile. Ant….
0
8
0
RT @may_daher: Congratulations @Dr_Nick_Bikes, Jai Rautela and team on this very elegant work! CRISPR screens will definitely advance the f….
0
4
0
RT @Dr_Nick_Bikes: Excited to share our Cancer Cell @CellPressNews article on the discovery of the IL-15 Receptor "Regulome". A technical t….
0
16
0